Evidence map›Paper›PMID 24731938›Full record

ArticleThe Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases

Pharmacodynamic profiling of commonly prescribed antimicrobial drugs against Escherichia coli isolates from urinary tract.

Gabriel Trova Cuba, Antonio Carlos Campos Pignatari, Katya Silva Patekoski, Lucimila Jorge Luchesi, Carlos Roberto Veiga Kiffer

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Antimicrobial Susceptibility ofMicroorganisms · 2025
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Gabriel Trova CubaLaboratório Especial de Microbiologia Clínica, Department of Infectology, Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brazil. Electronic address: gbtrova@gmail.com.
Antonio Carlos Campos PignatariLaboratório Especial de Microbiologia Clínica, Department of Infectology, Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brazil.
Katya Silva PatekoskiLaboratório Especial de Microbiologia Clínica, Department of Infectology, Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brazil.
Lucimila Jorge LuchesiLaboratório Especial de Microbiologia Clínica, Department of Infectology, Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brazil.
Carlos Roberto Veiga KifferLaboratório Especial de Microbiologia Clínica, Department of Infectology, Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since antimicrobial resistance among uropathogens against current first line agents has affected the management of severe urinary tract infection, we determined the likelihood that antibiotic regimens achieve bactericidal pharmacodynamic exposures using Monte Carlo simulation for five antimicrobials (ciprofloxacin, ceftriaxone, piperacillin/tazobactam, ertapenem, and meropenem) commonly prescribed as initial empirical treatment of inpatients with severe community acquired urinary tract infections. Minimum inhibitory concentration determination by Etest was performed for 205 Brazilian community urinary tract infection Escherichia coli strains from 2008 to 2012 and 74 E. coli bloodstream strains recovered from a surveillance study. Pharmacodynamic exposure was modeled via a 5000 subject Monte Carlo simulation. All isolates were susceptible to ertapenem and meropenem. Piperacillin/tazobactam, ceftriaxone and ciprofloxacin showed 100%, 97.5% and 83.3% susceptibility among outpatient isolates and 98.6%, 75.7% and 64.3% among inpatient isolates, respectively. Against outpatient isolates, all drugs except ciprofloxacin (82.7% in aggressive and 77.6% in conservative scenarios) achieved high cumulative fraction of response: carbapenems and piperacillin/tazobactam cumulative fraction of responses were close to 100%, and ceftriaxone cumulative fraction of response was 97.5%. Similar results were observed against inpatients isolates for carbapenems (100%) and piperacillin/tazobactam (98.4%), whereas ceftriaxone achieved only 76.9% bactericidal cumulative fraction of response and ciprofloxacin 61.9% (aggressive scenario) and 56.7% (conservative scenario) respectively. Based on this model, standard doses of beta-lactams were predicted to deliver sufficient pharmacodynamic exposure for outpatients. However, ceftriaxone should be avoided for inpatients and ciprofloxacin empirical prescription should be avoided in both inpatients and outpatients with complicated urinary tract infection.

Indexed as

Anti-Bacterial Agentsbeta-LactamsCeftriaxoneCiprofloxacinErtapenemEscherichia coliEscherichia coli InfectionsHumansMeropenemMicrobial Sensitivity TestsMonte Carlo MethodPenicillanic AcidPiperacillinPiperacillin, Tazobactam Drug CombinationPyelonephritisSeverity of Illness IndexAnti-Bacterial Agentsbeta-LactamsCeftriaxoneCiprofloxacinErtapenemMeropenemPenicillanic AcidPiperacillinPiperacillin, Tazobactam Drug CombinationThienamycinsEscherichia coliMonte Carlo methodPharmacodynamicsUrinary tract infection

Identifiers

PMID24731938
PMCPMC9428196

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.